ACE and heart failure: The majority of patients were under heart failure medication with angiotensin-converting enzyme inhibitors (ACE or angiotensin-1 receptor (AT1) inhibitors (70.5 vs. 56.1%), betablockers (89.5 vs. 78%), or aldosterone-antagonist (61.9 vs. 36.6%).